Patients and Families Health Care Professionals Contact Us
Aldurazyme Logo
Search

Go
Patients and Families
About MPS I
Genetics and MPS
Signs and Symptoms
Diagnosis and Testing
Treatment
Living with MPS I
Resources and Support
Full Prescribing Information (PDF)

Genes form the blueprint of heredity. They help guide our body's growth and development and determine traits such as eye color and height. People inherit two copies of every gene, one from each parent.

How MPS I is passed on
The genes that control the production of the enzymes that breakdown GAG (glycosaminoglycans) are passed from parent to child. In people with MPS I disease, one of these genes is faulty. As a result, not enough of the enzyme is produced or the available enzyme do not function properly.

MPS I disease is referred to as an autosomal recessive disorder. A person is born with the disease by inheriting two faulty MPS I genes, one from each parent. When only one MPS I gene is passed on to a person, he or she will not develop MPS I disease, but will become a carrier. A carrier can pass a mutated MPS I gene to his or her children.

The odds of passing on MPS I genes
When both parents are carriers, there is a 25% chance that each child will inherit two faulty genes and be born with MPS I disease. It is equally likely that the child will inherit two normal genes and be unaffected. With each pregnancy, there is a 50% chance that the child will receive just one mutated gene and become an unaffected carrier for the disease. The diagram below shows how the MPS I gene may be passed from one generation to the next.


Legend:

M - gene that properly controls production of the enzymes that breakdown GAG

MR -faulty gene, one that does not properly control production of the enzymes that breakdown GAG

Possible Outcomes When Both Parents Are Carriers:
  1. The child inherits two healthy copies of the gene, one from each parent (unaffected child).
  2. The child inherits one faulty copy of the gene from mother, one healthy gene from father (carrier child).
  3. The child inherits one faulty copy of the gene from father, one healthy copy of the gene from mother (carrier child).
  4. The child inherits two faulty copies of the gene, one from each parent (affected child).
Families affected by MPS I may wish to consult with their doctor or genetic counselor to discuss issues of genetic inheritance and family planning.

Prenatal Diagnosis: It is possible for parents who have a child with MPS I to have tests during a subsequent pregnancy to find out whether the baby being carried is affected. It is important to consult with a doctor as soon as the pregnancy is suspected to have tests arranged.

A genetic counselor may be a valuable resource to help you understand how MPS I is inherited in families. He or she may also provide guidance to families for diagnostic, medical, and support services. For more information about genetic counseling, please click here.


Region/Country
This site is intended for use in the United States. Please visit the Genzyme site for your country or region.
Even though people with MPS I have the same enzyme deficiency, they may experience a wide range of symptoms.
MPS I is a progressive, debilitating and often life-threatening disease. Tell us how you found this site and you may help others locate critical information about MPS I and its treatment.

ALDURAZYME® (laronidase) is indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms.  The risks and benefits of treating mildly affected patients with the Scheie form have not been established.

 

ALDURAZYME has been shown to improve pulmonary function and walking capacity.  ALDURAZYME has not been evaluated for effects on the central nervous system manifestations of the disorder.

 

Important Safety Information

 

WARNING

Risk of anaphylaxis.

Life-threatening anaphylactic reactions have been observed in some patients during ALDURAZYME infusions.  Therefore, appropriate medical support should be readily available when ALDURAZYME is administered.  Patients with compromised respiratory function or acute respiratory disease may be at risk of serious acute exacerbation of their respiratory compromise due to infusion reactions, and require additional monitoring.

 

Life-threatening anaphylactic reactions have been observed in some patients during or up to 3 hours after ALDURAZYME infusions. Reactions have included: respiratory failure, respiratory distress, stridor, tachypnea, bronchospasm, airway obstruction, hypoxia, hypotension, bradycardia, and urticaria. Interventions have included: resuscitation, mechanical ventilatory support, emergency tracheotomy, hospitalization, and treatment with inhaled beta-adrenergic agonists, epinephrine, and intravenous corticosteroids.

 

In clinical trials and postmarketing safety experience with ALDURAZYME, approximately 1% of patients experienced severe or serious allergic reactions. In patients with MPS I, pre-existing upper airway obstruction may have contributed to the severity of some reactions. Due to the potential for severe allergic reactions, appropriate medical support should be readily available when ALDURAZYME is administered. Because of the potential for recurrent reactions, some patients who experience initial severe reactions may require prolonged observation. The risks and benefits of re-administering ALDURAZYME following an anaphylactic or severe allergic reaction should be considered.

 

Patients with an acute illness at the time of ALDURAZYME infusion may be at greater risk for infusion-related reactions. Careful consideration should be given to the patient’s clinical status prior to administration of ALDURAZYME.

 

Patients should receive antipyretics and/or antihistamines prior to infusion. If an infusion reaction occurs, regardless of pretreatment, decreasing the infusion rate, temporarily stopping the infusion, and/or administration of additional antipyretics and/or antihistamines may ameliorate the symptoms.

 

The most common adverse reactions associated with ALDURAZYME treatment in the clinical studies were upper respiratory tract infection, rash, and injection site reaction  The most common adverse reactions requiring intervention were infusion-related reactions involving flushing, fever, headache, and rash. 

 

In postmarketing experience with ALDURAZYME, severe and serious infusion-related reactions have been reported, some of which were life-threatening.  The most frequently reported adverse reactions included: chills, vomiting, nausea, arthralgia, diarrhea, tachycardia, abdominal pain, blood pressure increased, and oxygen saturation decreased. 

 

Approximately 91% of patients treated with ALDURAZYME in clinical studies were positive for antibodies to laronidase. The clinical significance of antibodies to ALDURAZYME is not known, including the potential for product neutralization. Adverse events should be reported promptly to Genzyme Medical Information at 800-745-4447, option 2. ALDURAZYME is available by prescription only. To learn more, please see the full prescribing information (PDF) including boxed warning, visit www.ALDURAZYME.com or contact Genzyme at 1-800-745-4447.


Biomarin Logo Genzyme Logo